Piśmiennictwo

1. Hicks LA, Bartoces MG, Roberts RM, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis 2015;60:1308-16

2. Mohr KI. History of Antibiotics Research. W: Stadler M, Dersch P (red.). How to Overcome the Antibiotic Crisis . Current Topics in Microbiology and Immunology 2016;vol 398. Springer, Cham

3. Nicolaou KC, Rigol S. A brief history of antibiotics and select advances in their synthesis. J Antibiot 2018;71:153-84

4. Ribeiro Da Cunha B, Fonseca LP, Calado CRC. Antibiotic discovery: where have we come from, where do we go? Antibiotics (Basel) 2019;8:45

5. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011;24:71-109

6. WHO. 2021 antibacterial agents in clinical and preclinical development: an overview and analysis. World Health Organization 2022

7. Saga T, Yamaguchi K. History of Antimicrobial Agents and Resistant Bacteria. JMAJ 2009;52(2):103-8

8. CDC. Antibiotic resistance threats in the United States 2013. 2013

9. CDC. Antibiotic resistance threats in the United States 2019. 2019

10. Hutchings T et al. Antibiotics: past, present and future. Current Opinion in Microbiology 2019;51:72-80

11. Wright G. Q&A: Antibiotic resistance: where does it come from and what can we do about it? BMC Biol 2010;8:123

12. WHO. Antimicrobial resistance. WHO 2022. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (dostęp 2022.09.05)

13. Europejski Dzień Wiedzy o Antybiotykach. Publikacja Odpowiedzialne stosowanie antybiotyków. Informacja dla społeczeństwa. 18 listopada 2010 r. Kampania organizowana w ramach programu polityki zdrowotnej Ministra Zdrowia pn. Narodowy Program Ochrony Antybiotyków (NPOA 2010)

14. Komisja Europejska, EU Action on Antimicrobial Resistance [Działania UE w zakresie oporności na środki przeciwdrobnoustrojowe]. 2017

15. Antimicrobial Resistance Collaborators 2019. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022;399:629-55

16. Surveillance of antimicrobial resistance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2018

17. Narodowy Program Ochrony Antybiotyków (NPOA) przyjęty na lata 2016-2020

18. Bezpieczeństwo pacjentów przy stosowaniu antybiotykoterapii w szpitalach. NIK 2019 KZD.430.001.2019. Nr ewid. 40/2019/P/18/058/KZD s.8 https://www.nik.gov.pl/plik/id,20833,v,artykul_19634.pdf

19. O’neill J. Tackling Drug-Resistant Infections Globally: Final Report And Recommendations The Review On Antimicrobial Resistance Chaired By Jim O’neill. Welcome Trust and the UK Department of Health 2016

20. O’Neill J. Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations.2014

21. Klein E, Van Boeckel T, Martinez E, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA 2018;115:E3463-E3470

22. Costello EK et al. The application of ecological theory toward an understanding of the human microbiome. Science 2012;336:1255-62

23. European Centre for Disease Prevention and Control. Antimicrobial consumption in the EU/EEA (ESAC-Net) Annual Epidemiological Report 2020. Stockholm: ECDC 2021

24. Ben-Shimol S et al. On Behalf Of The Israel Bacteremia And Meningitis Active Surveillance Group. Impact of pneumococcal conjugate vaccines introduction on antibiotic resistance of Streptococcus pneumoniae meningitis in children aged 5 years or younger. Israel, 2004 to 2016. Euro Surveill 2018;23(47):1800081

25. Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect 2009;15 Suppl 3:16-20

26. Shehab N, Patel PR, Srinivasan A, et al. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008;47:735-43

28. Bong Ki Cha, Seung Mun Jung, Chang Hwan Choi, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012;46:220-7

29. Silverman MA, Konnikova L, Gerber JS. Impact of antibiotics on necrotizing enterocolitis and antibiotic-associated diarrhea. Gastroenterol Clin North Am 2017;46:61-76

30. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis (Basel Switz) 1998;16:292-307

31. Wilcox MH. Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis. Best Pract Res Clin Gastroenterol 2003;17: 475-93

32. Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004;42:1203-6

33. Song HJ, Shim KN, Jung SA, et al. Antibiotic-associated diarrhea: candidate organisms other than Clostridium difficile. Korean J Intern Med 2008;23: 9-15

34. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009;7:526-36

35. Becattini S, Taur Y, Pamer EG. Antibiotic-Induced Changes in the Intestinal Microbiota and Disease. Trends in Molecular Medicine 2016;22(6)

36. European Commission. Special Eurobarometer Report 478 – Antimicrobial Resistance. September 2018

37. Kopf T. Antibiotic Prescriptions in Respiratory Infections. Źródło: IQVIA

38. Worrall G. Acute sore throat. Can Fam Physician 2011;57(7):791-4

39. Fal AM i wsp. Diagnostyka i leczenie wybranych infekcji oraz stanów zapalnych dróg oddechowych. Wytyczne dla lekarzy POZ. Lekarz POZ 2021;7(5):325-53

40. Mazur E. Management of acute streptococcal pharyngitis: still the subject of controversy. Cent Eur J Med 2013;8(6):713-9

41. Zielnik-Jurkiewicz B. Zapalenie gardła i migdałków podniebiennych. W: Zielnik-Jurkiewicz B. Choroby laryngologiczne u dzieci. Wydanie II 2020

42. Poses R et al. The accuracy of experienced physician in probability estimates for patients with the sore throats: implications of decision making. JAMA 1985;254:925-9

43. Komaroff A et al. The prediction of streptococcal pharyngitis in adults. J Gen Intern Med 1986;1:1-7

44. Wen Kuan L et al. Epidemiology of Acute Respiratory Infections in Children in Guangzhou: A Three-Year Study. PLoS One 2014;9:e96674

45. Kuchar E, Wanke-Rytt M. Ostre zapalenie gardła i migdałków podniebiennych w świetle rekomendacji postępowania w pozaszpitalnych zakażeniach układu oddechowego 2016. Standardy Medyczne/Pediatria 2017:146-50

46. Hryniewicz W i wsp. Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego. Narodowy Program Ochrony Antybiotyków. Narodowy Instytut Leków. Warszawa 2016

47. Jędrzejek M et al. Rational use of antimicrobials in upper respiratory tract infections in the COVID-19 era. Lekarz POZ 2020;6(4)

48. Serwis Rzeczypospolitej Polskiej. Testy na COVID-19 https://www.gov.pl/web/koronawirus/zapisz-sie-na-test-na-koronawirusa (2022.08.23)

49. Köhnlein J, Rheinbaben FV, Werner S. Zur antimikrobiellen und viruziden Wirksamkeit von Octenidin-Lutschtabletten [On the antimicrobial and virucidal efficacy of octenidine lozenges] 2016;38(4):165-73

50. A randomised, multi-centre, parallel group, double-blind, placebo- and active-controlled clinical study to assess the efficacy and safety of Octenidine lozenges in the treatment of acute sore throat. EudraCT number: 2012-002876-15. https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002876-15/results (dostęp 2022.09.08)

51. Kehrl W et al. Therapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial. Laryngoscope 2004;114(4):738-42

52. Flores-Mireles AL et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 2015;13(5):269-84

53. Sihra N et al. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat Rev Urol 2018;15(12):750-76

54. Kopf T et al. Contribution of urinary tract infections to antibiotic consumption in Europe. In 1st International Electronic Conference on Antibiotics – The Equal Power of Antibiotics and Antimicrobial Resistance 2021

55. Allocati N et al. Escherichia coli in Europe: an overview. Int J Environ Res Public Health 2013;10(12):6235-54

56. Kahlmeter G, Ahman J, Matuschek E. Antimicrobial Resistance of Escherichia coli Causing Uncomplicated Urinary Tract Infections: A European Update for 2014 and Comparison with 2000 and 2008. Infect Dis Ther 2015;4(4): 417-23

57. Lee DS, Lee SJ, Choe HS. Community-Acquired Urinary Tract Infection by Escherichia coli in the Era of Antibiotic Resistance. Biomed Res Int 2018. 2018:7656752

58. Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect 2008(14);6:2-8

59. Beerepoot M, Geerlings S. Non-Antibiotic Prophylaxis for Urinary Tract Infections. Pathogens 2016;5(2)

60. Ternes B, Wagenlehner FME. Guideline-based treatment of urinary tract infections. Urologe A 2020;59(5):550-8

61. Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med 2017;129(2):242-58

62. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2019. https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2019 (2022.09.14)

63. Center for Disease Dynamics, Economics & Policy https://resistancemap.cddep.org/CountryPage.php?countryId=28&country=Poland (2022.09.14)

64. Stefaniuk E et al. Etiology and antibiotic susceptibility of bacterial pathogens responsible for community-acquired urinary tract infections in Poland. Eur J Clin Microbiol Infect Dis 2016;35(8):1363-9. doi: 10.1007/s10096-016-2673-1. Epub 2016 May 18 PMID:27189078;PMCID: PMC4947106

65. Wojciechowska M i wsp. Lekowrażliwość bakterii wywołujących zakażenia układu moczowego u dzieci − obserwacje własne ośrodka. Forum Medycyny Rodzinnej 2017;11(1):21-5

66. Hryniewicz W, Holecki M. Rekomendacje diagnostyki, terapii i profilaktyki zakażeń układu moczowego u dorosłych. Narodowy Instytut Leków, Warszawa 2015

67. Le VVH, Rakonjac J. Nitrofurans: Revival of an „old” drug class in the fight against antibiotic resistance. PLoS Pathog 2021;8;17(7):e1009663

68. Kranz J et al. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int 2018;100(3):271-8

69. Bonkat G et al. EAU Guidelines on Urological Infections. European Association of Urology 2020

70. Hulscher MEJL, Grol RPTM, van der Meer JWM. Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infect Dis 2010;10;167-75

71. Silver SA et al. Positive urine cultures: A major cause of inappropriate antimicrobial use in hospitals ? Can J Infect Dis Med Microbiol 2009;20:107

72. Bonkat G, Bartoletti R, Bruyere F, et al. EAU Guidelines 2022 on Urological Infections

73. Widmar M et al. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cocharane Database Syst Rev 2015:CD000491

74. Bell BG et al. A systematic review and meta-analysis of the effect of antibiotic consumption and antibiotic resistance. BMC Infect Dis 2014;14:13

75. Kronenberg A et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomized, double blind trial. BMJ;2017;359:4784

76. Schuts EC et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis 2016;16:847

77. European Expert Board for Urinary Tract Infections. Opinion and recommendation statement: Treatment of UTI s – Quo vadis? November 2021